An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...

Clustered regularly interspaced palindromic repeats(CRISPR) gene editing, known for its precision, is revolutionizing tumor research and treatment. This article covers the evolution of the CRISPR ...

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

Ben Lamm, founder of Colossal Biosciences, aims to revive extinct species like the woolly mammoth using advanced genetic ...